{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:06:11Z","timestamp":1787317571249,"version":"build-2736575974"},"reference-count":60,"publisher":"MDPI AG","issue":"5","license":[{"start":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T00:00:00Z","timestamp":1589932800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancers"],"abstract":"<jats:p>Lymphoma is listed among the neoplasias with a high risk of venous thromboembolism (VTE). Risk factors for VTE appear to differ from risk factors in solid tumors. We review the literature of the last 20 years for reports identifying these risk factors in cohorts consisting exclusively of lymphoma patients. We selected 25 publications. The most frequent studies were analyses of retrospective single-center cohorts. We also included two reports of pooled analyses of clinical trials, two meta-analyses, two analyses of patient registries, and three analyses of population-based databases. The VTE risk is the highest upfront during the first two months after lymphoma diagnosis and decreases over time. This upfront risk may be related to tumor burden and the start of chemotherapy as contributing factors. Factors consistently reported as VTE risk factors are aggressive histology, a performance status ECOG \u2265 2 leading to increased immobility, more extensive disease, and localization to particular sites, such as central nervous system (CNS) and mediastinal mass. Association between laboratory values that are part of risk assessment models in solid tumors and VTE risk in lymphomas are very inconsistent. Recently, VTE risk scores for lymphoma were developed that need further validation, before they can be used for risk stratification and primary prophylaxis. Knowledge of VTE risk factors in lymphomas may help in the evaluation of the individual risk-benefit ratio of prophylaxis and help to design prospective studies on primary prophylaxis in lymphoma.<\/jats:p>","DOI":"10.3390\/cancers12051291","type":"journal-article","created":{"date-parts":[[2020,5,20]],"date-time":"2020-05-20T10:37:38Z","timestamp":1589971058000},"page":"1291","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Venous Thromboembolism in Lymphoma: Risk Stratification and Antithrombotic Prophylaxis"],"prefix":"10.3390","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5534-7197","authenticated-orcid":false,"given":"Stefan","family":"Hohaus","sequence":"first","affiliation":[{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Bartolomei","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annarosa","family":"Cuccaro","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Maiolo","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eleonora","family":"Alma","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"D\u2019Al\u00f2","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Bellesi","sequence":"additional","affiliation":[{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Rossi","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerio De","family":"Stefano","sequence":"additional","affiliation":[{"name":"Dipartimento di Scienze Radiologiche ed Ematologiche, Universit\u00e0 Cattolica del Sacro Cuore, 00168 Rome, Italy"},{"name":"Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli, IRCCS, L.go A. Gemelli, 8, 00168 Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2020,5,20]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"S112","DOI":"10.1016\/j.thromres.2018.01.028","article-title":"Morbidity, mortality and costs associated with venous thromboembolism in hospitalized patients with cancer","volume":"164","author":"Lyman","year":"2018","journal-title":"Thromb. Res."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"e566","DOI":"10.1016\/S1470-2045(19)30336-5","article-title":"2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer","volume":"20","author":"Farge","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1200\/JCO.19.01461","article-title":"Venous Thromboembolism Prophylaxis and Treatment in Patients with Cancer: ASCO Clinical Practice Guideline Update","volume":"38","author":"Key","year":"2020","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"312","DOI":"10.4143\/crt.2014.266","article-title":"Cross-sectional Study of Patients with Diffuse Large B-Cell Lymphoma: Assessing the Effect of Host Status, Tumor Burden, and Inflammatory Activity on Venous Thromboembolism","volume":"48","author":"Lim","year":"2016","journal-title":"Cancer Res. Treat."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1002\/ajh.24466","article-title":"Development and validation of multivariable predictive model for thromboembolic events in lymphoma patients","volume":"91","author":"Antic","year":"2016","journal-title":"Am. J. Hematol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1038\/s41408-018-0096-1","article-title":"Risk factors for venous thromboembolism in patients with lymphoma requiring hospitalization","volume":"8","author":"Hohaus","year":"2018","journal-title":"Blood Cancer J."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1093\/annonc\/mdz168","article-title":"Thrombosis as a treatment complication in Hodgkin lymphoma patients: A comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials","volume":"30","author":"Borchmann","year":"2019","journal-title":"Ann. Oncol. Off. J. Eur. Soc. Med. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.thromres.2010.08.017","article-title":"Increased risk of venous thromboembolism in patients with primary mediastinal large B-cell lymphoma","volume":"126","author":"Lekovic","year":"2010","journal-title":"Thromb. Res."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"35404","DOI":"10.18632\/oncotarget.8639","article-title":"High risk of deep vein thrombosis associated with peripherally inserted central catheters in lymphoma","volume":"7","author":"Zhang","year":"2016","journal-title":"Oncotarget"},{"key":"ref_12","first-page":"5","article-title":"Evaluation of the ThroLy score for the prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies in clinical practice","volume":"35","author":"Gil","year":"2018","journal-title":"Cancer Med."},{"key":"ref_13","first-page":"5","article-title":"Prediction of venous thromboembolism in newly diagnosed patients treated for lymphoid malignancies: Validation of the Khorana Risk Score","volume":"35","author":"Gil","year":"2017","journal-title":"Med. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/sj.bjc.6602945","article-title":"Increased risk of venous thromboembolism in patients with acute leukaemia","volume":"94","author":"Mohren","year":"2006","journal-title":"Br. J. Cancer"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1016\/j.amjmed.2010.05.021","article-title":"Incidence and risk factors of venous thromboembolic events in lymphoma","volume":"123","author":"Zhou","year":"2010","journal-title":"Am. J. Med."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1080\/10428190600560991","article-title":"Venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"47","author":"Komrokji","year":"2006","journal-title":"Leuk. Lymphoma"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1080\/10428194.2016.1185782","article-title":"Incidence of venous thromboembolism in patients with diffuse large B-cell lymphoma","volume":"57","author":"Borg","year":"2016","journal-title":"Leuk. Lymphoma"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1002\/cncr.11623","article-title":"High incidence of thromboembolism in patients with central nervous system lymphoma","volume":"98","author":"Goldschmidt","year":"2003","journal-title":"Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.thromres.2011.09.022","article-title":"Incidence and risk factors for developing venous thromboembolism in Japanese with diffuse large b-cell lymphoma","volume":"130","author":"Yokoyama","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.thromres.2019.10.002","article-title":"Incidence and characteristics of venous thromboembolism in Asian patients with primary central nervous system lymphoma undergoing chemotherapy","volume":"183","author":"Byun","year":"2019","journal-title":"Thromb. Res."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.thromres.2014.08.021","article-title":"Lupus anticoagulant and thrombosis in splenic marginal zone lymphoma","volume":"134","author":"Gebhart","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1160\/TH16-11-0895","article-title":"Khorana score and histotype predicts incidence of early venous thromboembolism in non-Hodgkin lymphomas. A pooled-data analysis of 12 clinical trials of Fondazione Italiana Linfomi (FIL)","volume":"117","author":"Santi","year":"2017","journal-title":"Thromb. Haemost."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"5322","DOI":"10.1182\/blood-2010-01-258624","article-title":"Thrombotic complications in adult patients with lymphoma: A meta-analysis of 29 independent cohorts including 18,018 patients and 1149 events","volume":"115","author":"Caruso","year":"2010","journal-title":"Blood"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1429","DOI":"10.1182\/bloodadvances.2018016683","article-title":"Venous thromboembolism in patients with B-cell non-Hodgkin lymphoma treated with lenalidomide: A systematic review and meta-analysis","volume":"2","author":"Yamshon","year":"2018","journal-title":"Blood Adv."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.thromres.2016.05.008","article-title":"Incidence of venous thromboembolism in patients with non-Hodgkin lymphoma","volume":"143","author":"Sanfilippo","year":"2016","journal-title":"Thromb. Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"4498","DOI":"10.1002\/cncr.32488","article-title":"Risk of venous thromboembolism in patients with non-Hodgkin lymphoma surviving blood or marrow transplantation","volume":"125","author":"Gangaraju","year":"2019","journal-title":"Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"S23","DOI":"10.1016\/S0049-3848(14)50004-7","article-title":"Lymphoma and venous thromboembolism: Influence on mortality","volume":"133","author":"Mahajan","year":"2014","journal-title":"Thromb. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.thromres.2015.09.001","article-title":"Incidence, determinants and the transient impact of cancer treatments on venous thromboembolism risk among lymphoma patients in Denmark","volume":"136","author":"Lund","year":"2015","journal-title":"Thromb. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1816","DOI":"10.1111\/jth.12724","article-title":"Elevated risk of venous but not arterial thrombosis in Waldenstrom macroglobulinemia\/lymphoplasmacytic lymphoma","volume":"12","author":"Hultcrantz","year":"2014","journal-title":"J. Thromb. Haemost."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"e6","DOI":"10.1016\/j.thromres.2012.03.019","article-title":"Incidence, risk factors and clinical features of venous thromboembolism in newly diagnosed lymphoma patients: Results from a prospective cohort study with Asian population","volume":"130","author":"Park","year":"2012","journal-title":"Thromb. Res."},{"key":"ref_31","doi-asserted-by":"crossref","unstructured":"Abdol Razak, N.B., Jones, G., Bhandari, M., Berndt, M.C., and Metharom, P. (2018). Cancer-Associated Thrombosis: An Overview of Mechanisms, Risk Factors, and Treatment. Cancers, 10.","DOI":"10.3390\/cancers10100380"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1016\/S0049-3848(13)70024-0","article-title":"Mechanisms of thrombosis in cancer","volume":"131","author":"Falanga","year":"2013","journal-title":"Thromb. Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.critrevonc.2017.08.003","article-title":"Mechanisms and risk factors of thrombosis in cancer","volume":"118","author":"Falanga","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"(1993). A predictive model for aggressive non-Hodgkin\u2019s lymphoma. New Engl. J. Med., 329, 987\u2013994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1200\/JCO.2005.03.8877","article-title":"Thromboembolism in hospitalized neutropenic cancer patients","volume":"24","author":"Khorana","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1001\/archinte.165.15.1782","article-title":"Incidence of venous thromboembolism in the year before the diagnosis of cancer in 528,693 adults","volume":"165","author":"White","year":"2005","journal-title":"Arch. Intern. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1001\/jama.293.6.715","article-title":"Malignancies, prothrombotic mutations, and the risk of venous thrombosis","volume":"293","author":"Blom","year":"2005","journal-title":"JAMA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.12778","article-title":"Factor V Leiden mutation increases the risk for venous thromboembolism in cancer patients\u2014Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"13","author":"Pabinger","year":"2015","journal-title":"J. Thromb. Haemost."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"37","DOI":"10.2302\/kjm.2014-0017-RE","article-title":"Thrombosis in Lymphoma Patients and in Myeloma Patients","volume":"64","author":"Yokoyama","year":"2015","journal-title":"Keio J. Med."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1200\/JCO.2009.27.6873","article-title":"Anemia in Hodgkin\u2019s lymphoma: The role of interleukin-6 and hepcidin","volume":"28","author":"Hohaus","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"670","DOI":"10.1160\/TH13-07-0603","article-title":"Association of mean platelet volume with risk of venous thromboembolism and mortality in patients with cancer. Results from the Vienna Cancer and Thrombosis Study (CATS)","volume":"111","author":"Riedl","year":"2014","journal-title":"Thromb. Haemost."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3324\/haematol.2014.109470","article-title":"Evaluation of mean platelet volume as a predictive marker for cancer-associated venous thromboembolism during chemotherapy","volume":"99","author":"Ferroni","year":"2014","journal-title":"Haematologica"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"21190","DOI":"10.18632\/oncotarget.25002","article-title":"Mean platelet volume as a predictive marker for venous thromboembolism in patients treated for Hodgkin lymphoma","volume":"9","author":"Gil","year":"2018","journal-title":"Oncotarget"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1002\/hon.2321","article-title":"Mean platelet volume as a predictive marker for venous thromboembolism and mortality in patients treated for diffuse large B-cell lymphoma","volume":"35","author":"Gil","year":"2017","journal-title":"Hematol. Oncol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.thromres.2016.12.013","article-title":"The Khorana score for the prediction of venous thromboembolism in patients with pancreatic cancer","volume":"150","author":"Franke","year":"2017","journal-title":"Thromb. Res."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1111\/jth.13378","article-title":"Predictors of active cancer thromboembolic outcomes: Validation of the Khorana score among patients with lung cancer","volume":"14","author":"Mansfield","year":"2016","journal-title":"J. Thromb. Haemost."},{"key":"ref_48","unstructured":"van Es, N., Ventresca, M., Di Nisio, M., Zhou, Q., Noble, S., Crowther, M., Briel, M., Garcia, D., Lyman, G.H., and Macbeth, F. (2020). The Khorana score for prediction of venous thromboembolism in cancer patients: An individual patient data meta-analysis. J. Thromb. Haemost."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.3324\/haematol.2018.209114","article-title":"The Khorana score for prediction of venous thromboembolism in cancer patients: A systematic review and meta-analysis","volume":"104","author":"Mulder","year":"2019","journal-title":"Haematologica"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1634\/theoncologist.2016-0246","article-title":"Preventing Venous Thromboembolism in Ambulatory Cancer Patients: The ONKOTEV Study","volume":"22","author":"Cella","year":"2017","journal-title":"Oncologist"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/s41416-018-0027-8","article-title":"Multivariable clinical-genetic risk model for predicting venous thromboembolic events in patients with cancer","volume":"118","author":"Ortega","year":"2018","journal-title":"Br. J. Cancer"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1016\/S2352-3026(18)30063-2","article-title":"A clinical prediction model for cancer-associated venous thromboembolism: A development and validation study in two independent prospective cohorts","volume":"5","author":"Pabinger","year":"2018","journal-title":"Lancet Haematol."},{"key":"ref_53","first-page":"171","article-title":"Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: An expert consensus","volume":"17","author":"Napolitano","year":"2019","journal-title":"Blood Transfus."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1056\/NEJMoa1711948","article-title":"Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism","volume":"378","author":"Raskob","year":"2018","journal-title":"New Engl. J. Med."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1200\/JCO.2018.78.8034","article-title":"Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D)","volume":"36","author":"Young","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1111\/jth.14662","article-title":"Apixaban and dalteparin in active malignancy-associated venous thromboembolism: The ADAM VTE trial","volume":"18","author":"McBane","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1056\/NEJMoa1915103","article-title":"Apixaban for the Treatment of Venous Thromboembolism Associated with Cancer","volume":"382","author":"Agnelli","year":"2020","journal-title":"New Engl. J. Med."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.thromres.2019.11.007","article-title":"Edoxaban for treatment of venous thromboembolism in patient groups with different types of cancer: Results from the Hokusai VTE Cancer study","volume":"185","author":"Mulder","year":"2020","journal-title":"Thromb. Res."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1056\/NEJMoa1814468","article-title":"Apixaban to Prevent Venous Thromboembolism in Patients with Cancer","volume":"380","author":"Carrier","year":"2019","journal-title":"New Engl. J. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1056\/NEJMoa1814630","article-title":"Rivaroxaban for Thromboprophylaxis in High-Risk Ambulatory Patients with Cancer","volume":"380","author":"Khorana","year":"2019","journal-title":"New Engl. J. Med."}],"container-title":["Cancers"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1291\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T09:30:39Z","timestamp":1760175039000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2072-6694\/12\/5\/1291"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,20]]},"references-count":60,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2020,5]]}},"alternative-id":["cancers12051291"],"URL":"https:\/\/doi.org\/10.3390\/cancers12051291","relation":{},"ISSN":["2072-6694"],"issn-type":[{"value":"2072-6694","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,20]]}}}